The optimistic anti-coagulation regimen for patients underwent total knee arthroplasty under the background of enhanced recovery after surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029238

Enrollment

Unknown

Registered

2020-01-19

Start date

2020-02-01

Completion date

Unknown

Last updated

2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee joint disease

Interventions

A:Rivaroxaban 10mg per day after surgery

B:aspirin 100mg per day after surgery

C:chemotherapy sparing

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) unilateral primary total knee arthroplasty candidate whose diagnosis is knee osteoarthritis; (2) aged 50 to 80 years; (3) Understand the risk and benefit and comply with the study protocol.

Exclusion criteria

Exclusion criteria: 1. Patients who received other surgery or anticoagulant drugs within three months; 2. There is at least one risk factor for thrombosis: previous history of DVT, PE, myocardial infarction (MI), stroke (CVA), transient ischemic attack (TIA), post-coronary stenting, post-coronary artery bypass grafting, and hypercoagulable state of blood; 3. Within 6 hours after TKA patients who cannot stand on the ground; 4. Vein thrombosis patients before surgery; 5. Inability to provide informed consent due to mental incompetence (e.g., intellectual disability, dementia).

Design outcomes

Primary

Measure	Time frame
Hemoglobin drop on the 1st and 3rd day after surgery;Deep venous thrombosis incidence;	—

Secondary

Measure	Time frame
blood loss;D-Dimer elevation after surgery;ecchymosis incidence after surgery;	—

Countries

China

Contacts

Public ContactLi Hui

Xi'an Honghui Hospital

lihui327@163.com+86 18700788587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026